Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 1984.42% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 1775.98% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 1880.2% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1254.87% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 2088.64% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1359.09% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 2088.64% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 1671.76% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1254.87% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1359.09% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 2192.86% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 1880.2% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 1984.42% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1359.09% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1150.65% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 837.99% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 1775.98% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1463.31% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/05/2023 | - | Jones Trading | 評級下調 | 購買→Hold | |
| 09/25/2023 | 1984.42% | HC Wainwright公司 | $18→$20 | 維護 | 買 |
| 2023年08月11日 | - | 富國銀行 | 評級下調 | 超重→等重 | |
| 2023年08月11日 | 1775.98% | HC Wainwright公司 | $19→$18 | 維護 | 買 |
| 2023年05月12日 | 1880.2% | HC Wainwright公司 | $21→$19 | 維護 | 買 |
| 2023年05月12日 | 1254.87% | 富國銀行 | $14→$13 | 維護 | 超重 |
| 03/16/2023 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 03/16/2023 | 2088.64% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 01/03/2023 | 1359.09% | 富國銀行 | $17→$14 | 維護 | 超重 |
| 2022年08月12日 | 2088.64% | HC Wainwright公司 | $20→$21 | 維護 | 買 |
| 2022/06/28 | 1671.76% | 富國銀行 | $13→$17 | 維護 | 超重 |
| 2022年05月13日 | 1254.87% | 富國銀行 | $14→$13 | 維護 | 超重 |
| 05/04/2022 | 1359.09% | 富國銀行 | $19→$14 | 維護 | 超重 |
| 03/18/2022 | 2192.86% | HC Wainwright公司 | $20→$22 | 維護 | 買 |
| 12/08/2021 | 1880.2% | 富國銀行 | →$19 | 開始承保 | →超重 |
| 2021年11月16日 | 1984.42% | HC Wainwright公司 | $12→$20 | 維護 | 買 |
| 07/20/2021 | 1359.09% | Jones Trading | →$14 | 開始承保 | →購買 |
| 06/04/2020 | 1150.65% | HC Wainwright公司 | $9→$12 | 維護 | 買 |
| 05/05/2020 | 837.99% | HC Wainwright公司 | $15→$9 | 重申 | →購買 |
| 03/13/2020 | 1775.98% | 富國銀行 | $30→$18 | 維護 | 超重 |
| 2019年07月29日 | 1463.31% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
What is the target price for Kezar Life Sciences (KZR)?
Kezar生命科學公司(KZR)的目標價是多少？
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by JonesTrading on October 5, 2023. The analyst firm set a price target for $0.00 expecting KZR to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
瓊恩斯交易公司於2023年10月5日報道了科扎生命科學公司(納斯達克代碼：KZR)的最新目標價。這家分析公司將KZR的目標價設定為0.00美元，預計KZR將在12個月內下跌(可能下跌-100.00%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的最新分析師評級是多少？
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by JonesTrading, and Kezar Life Sciences downgraded their hold rating.
凱撒生命科學(納斯達克代碼：KZR)的最新分析師評級由瓊恩斯交易公司提供，凱撒生命科學下調了其持有評級。
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on October 5, 2023 so you should expect the next rating to be made available sometime around October 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Kezar Life Science的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Kezar生命科學的上一次評級是在2023年10月5日提交的，所以你應該預計下一次評級將在2024年10月5日左右的某個時候提供。
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
分析師對Kezar Life Science(KZR)的評級正確嗎？
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Kezar Life Sciences (KZR) is trading at is $0.96, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Kezar Life Science(KZR)評級被下調，目標價為0.00美元至0.00美元。Kezar Life Science(KZR)目前的股價為0.96美元，超出了分析師的預測範圍。